The FDA has approved Baxter International Inc's (NYSE: BAX) next-generation Artificial Kidney 98 (AK 98) dialysis machine.
- AK 98 Offers a compact, portable, and easy-to-use system for dialysis.
- AK 98 offers encrypted, two-way connectivity, enabling the system to pull prescriptions directly from the electronic medical record for simplified workflow and data handling.
- AK 98 is currently used in more than 90 countries globally and will be available in the U.S. in the coming weeks.
- The dialysis system can be used alongside Theranova, Baxter's novel dialysis membrane.
- Price Action: BAX shares were trading 1.3% higher at $78.74 in premarket trading on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in